Nexviazyme Patient Assistance Program

(avalglucosidase alfa-ngpt)

Key Takeaways

  1. Nexviazyme® (avalglucosidase alfa-ngpt) is an enzyme replacement therapy (ERT) approved for the treatment of late-onset Pompe disease in adults and pediatric patients 1 year of age and older weighing at least 30 kg.
  2. Nexviazyme replaces the deficient acid alpha-glucosidase (GAA) enzyme, helping reduce glycogen accumulation in muscle cells associated with Pompe disease.
  3. Nexviazyme does not carry an FDA Boxed Warning. However, patients should be monitored for serious hypersensitivity reactions, infusion-associated reactions, and acute cardiorespiratory compromise.
  4. Nexviazyme is administered by intravenous infusion every 2 weeks, and lifelong treatment is generally required for Pompe disease.
  5. Prescription Hope may help eligible individuals access manufacturer-sponsored patient assistance programs that can make Nexviazyme more affordable.

 

Introduction

Late-onset Pompe disease is a rare inherited disorder caused by a deficiency of the acid alpha-glucosidase (GAA) enzyme, leading to glycogen buildup in skeletal muscle and other tissues. Over time, this accumulation can contribute to progressive muscle weakness and respiratory problems.

Nexviazyme is an enzyme replacement therapy designed to replace the missing GAA enzyme and help reduce glycogen accumulation in patients with late-onset Pompe disease. It is approved for adults and eligible pediatric patients and is administered by intravenous infusion as an ongoing treatment.

Many people needing the Nexviazyme patient assistance program are looking for ways to reduce their prescription costs. Prescription assistance programs may help eligible patients obtain Nexviazyme at a more affordable cost.

Prescription Hope provides qualified patients with access to affordable medications through patient assistance programs.

What Is the Nexviazyme Patient Assistance Program?

Understanding Nexviazyme Prescription Assistance

Patients needing affordable Nexviazyme may benefit from the Nexviazyme patient assistance program. However, many may not even know what a patient assistance program is.

Pharmaceutical manufacturers offer patient assistance programs to qualified patients which give access to brand-name medications at affordable rates.

Criteria for approval fall under general categories, such as income, insurance, and residency.

However, patient assistance programs have been known to be difficult to apply for.

Thankfully, Prescription Hope has a solution.

How Expert Advocates Help Make Nexviazyme More Affordable

Personalized Medication Assistance

Prescription Hope provides patient support services for qualified patients seeking to access medication at affordable rates through patient assistance programs.

Our team of patient advocates handles forms, document and signature collection, coordination with healthcare providers and manufacturers, and much more.

Ongoing Patient Support

After approval, Prescription Hope’s rare disease medication assistance services also continue to manage a patient’s enrollment status. We handle administrative tasks associated with patient assistance programs. These may include document updates, yearly renewals, issue resolution, and even refill scheduling.

Nexviazyme Price Comparison

vs

Prescription Hope logo

Estimated Retail Price*

$1,987.34

30-Day Supply

Prescription Hope Price

$70

Per Month, NO Matter The Retail Price

*Source: Drugs.com

Navigating Rare Disease Treatment Costs

Unfortunately, rare disease medications such as Nexviazyme are often expensive for those who need to pay out of pocket. This has Americans searching for prescription cost help and medication financial assistance.

Prescription Hope offers all of our medication access services for a simple $70.00 per month, per medication. This means no hassles or hidden fees, no add-on charges, and no medication costs.

And if we can’t help you save on your monthly medication costs, then you pay nothing!

Nexviazyme Patient Assistance Eligibility

General Eligibility Requirements

Those curious about Nexviazyme eligibility can learn more by simply enrolling with Prescription Hope. While all programs maintain strict requirements, each differs in the specific criteria used.

However, the general categories of requirements include:

Income: All programs differ in the income range used for approval.

Insurance: Each program differs in the status of insurance coverage that is acceptable for approval.

Prescription: Every program requires a qualified patient to have a valid prescription for their medication.

U.S. residency: All qualified patients must be legal U.S. residents.

Simple Enrollment With Expert Support

Getting Started With Enrollment

Those who are looking to enroll in Nexviazyme assistance can simply follow Prescription Hope’s 6 steps:

  1. Submit your form: Our online enrollment form can be completed in just a few minutes.
  2. Advocate Contact: After receiving your completed enrollment form, a patient advocate will reach out within 1-2 business days.
  3. Document Collection: Once we prequalify you, our team then collects all documentation required by the manufacturer
  4. Provider Coordination: We coordinate with your healthcare provider to secure necessary signatures.
  5. Program Submission: Our team submits your application and follows up with the manufacturer throughout the processing stage.
  6. Medication Delivery: After approval, patients typically receive their medication within 2 weeks. All medications are shipped directly from the manufacturer to your door or doctor’s office.

Prescription Hope is not a pharmacy or manufacturer, and therefore does not handle medication at any time.

Understanding Nexviazyme

How Nexviazyme Works

Nexviazyme contains avalglucosidase alfa-ngpt, a recombinant human acid alpha-glucosidase (GAA) enzyme.

The medication is engineered with an increased number of mannose-6-phosphate (M6P) residues compared with earlier enzyme replacement therapies, enhancing cellular uptake through mannose-6-phosphate receptor-mediated transport into lysosomes.

After intravenous administration, avalglucosidase alfa-ngpt is internalized into lysosomes, where it breaks down accumulated glycogen into glucose. This helps reduce lysosomal glycogen storage and improves cellular function in affected tissues, particularly skeletal muscle.

What Conditions Does Nexviazyme Treat?

Nexviazyme is FDA-approved for the treatment of:

  • Late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) in adults and pediatric patients 1 year of age and older weighing at least 30 kg

Pompe disease is a rare, inherited lysosomal storage disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA), resulting in glycogen accumulation in skeletal muscle, cardiac muscle, and other tissues.

Nexviazyme is an enzyme replacement therapy that provides exogenous acid alpha-glucosidase to help reduce lysosomal glycogen accumulation in patients with late-onset Pompe disease.

Benefits of Treatment

For appropriate patients with late-onset Pompe disease, Nexviazyme may:

  • Replace deficient acid alpha-glucosidase enzyme activity.
  • Reduce glycogen accumulation within lysosomes.
  • Have demonstrated improvement or stabilization of walking ability in clinical studies
  • May help maintain or improve respiratory function in some patients
  • Slow progression of muscle weakness
  • Provide enhanced enzyme uptake compared with earlier enzyme replacement therapies through increased mannose-6-phosphate receptor targeting.

Individual treatment response varies, and ongoing therapy is generally required throughout life.

Important Safety Information and Side Effects

Nexviazyme does not carry an FDA Boxed Warning.

Contraindications

The FDA Prescribing Information lists no contraindications for Nexviazyme.

The most commonly reported adverse reactions include:

  • Infusion-associated reactions
  • Headache
  • Fatigue
  • Nausea
  • Diarrhea
  • Vomiting
  • Arthralgia (joint pain)
  • Myalgia (muscle pain)
  • Pruritus (itching)
  • Chills
  • Dizziness
  • Erythema (skin redness)

Infusion-associated reactions may occur during or shortly after administration.

Patients should notify their healthcare provider immediately if they develop symptoms of a severe allergic or infusion-related reaction.

Patients should discuss the following risks with their healthcare provider:

  • Serious hypersensitivity reactions, including anaphylaxis
  • Severe infusion-associated reactions
  • Acute cardiorespiratory compromise in susceptible patients
  • Risk associated with infusion during acute illness
  • Development of anti-drug antibodies, which may be associated with reduced treatment response or increased risk of infusion-associated reactions

Patients should be closely monitored during and after infusions, particularly during the initial months of therapy.

Available human data are insufficient to determine whether Nexviazyme increases the risk of major birth defects or miscarriage. Animal studies have not identified significant developmental toxicity at clinically relevant exposures. The benefits of treatment should be weighed against any potential risks during pregnancy. Patients who become pregnant should discuss continued treatment with their healthcare provider.

It is not known whether avalglucosidase alfa-ngpt is present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Nexviazyme and any potential adverse effects on the breastfed infant.

No formal clinical drug interaction studies have identified clinically significant pharmacokinetic drug interactions with Nexviazyme. Healthcare providers should review all prescription medications, over-the-counter products, vitamins, and herbal supplements before treatment.

Nexviazyme is administered by intravenous infusion at the recommended dosage of 20 mg/kg every 2 weeks. Infusion duration depends on patient weight, infusion rate, and individual tolerability. Infusion rates should be increased gradually according to the prescribing information if tolerated. Premedication with antihistamines, antipyretics, and/or corticosteroids may be considered to reduce infusion-associated reactions. Patients should be monitored during and after each infusion for signs of hypersensitivity or infusion-related reactions.

Access to Multiple Medications

Support Beyond Nexviazyme

Patients seeking access to more than one brand-name medication at affordable rates may benefit from multiple medication assistance programs.

For $70.00 per month, per medication, Prescription Hope can help qualified patients access every medication they qualify for through our services.

Why Choose Prescription Hope

Patient-Focused Medication Support

For 20 years, Prescription Hope has offered patient-centered prescription help services to Americans across the nation.

Hundreds of thousands of patients have come to trust our team of specialists for advocacy and support.

Simplified Access to Prescription Medications

Our patient assistance services are all included in our simple $70.00 per month, per medication.

Ongoing Prescription Assistance

Prescription Hope not only helps patients with their patient assistance program application, but we also help with long-term medication support. Our team of patient advocates continues to manage your administrative tasks long after approval, including refill scheduling, document updates, yearly renewals, program monitoring, and issue resolution.

If you need affordable Nexviazyme and don’t know where to turn, then enroll with Prescription Hope today and find out how we can help you save on your monthly medication costs!

 

Frequently Asked Questions

It's Easy!

Submit Enrollment Form

Getting started is free and easy! Simply complete the online enrollment form. 

Receive Welcome Call

An Enrollment Specialist will reach out to you for a personalized welcome call.

We Manage The Process

Your dedicated team manages your account month after month, allowing you to focus on what matters most—your health.

Helpful Articles

Latest News & Stories

Save Money On Your Prescriptions Today!